1-[(Pyridin-3-yl)methyl]piperazine → [4-(4-{2-[Bis-(4-methoxy-benzyl)-amino]-pyrimidin-5-yl}-2-morpholin-4-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-7-yl)-3-fluoro-phenyl]-(4-pyridin-3-ylmethyl-piperazin-1-yl)-methanone

HRID 912383

Reaktionsgleichung

Reaktionsgleichung von HRID 912383
[CH3:1][O:2][C:3]1[CH:50]=[CH:49][C:6]([CH2:7][N:8]([CH2:40][C:41]2[CH:46]=[CH:45][C:44]([O:47][CH3:48])=[CH:43][CH:42]=2)[C:9]2[N:14]=[CH:13][C:12]([C:15]3[C:16]4[CH2:29][CH2:28][N:27]([C:30]5[CH:38]=[CH:37][C:33]([C:34]([OH:36])=O)=[CH:32][C:31]=5[F:39])[C:17]=4[N:18]=[C:19]([N:21]4[CH2:26][CH2:25][O:24][CH2:23][CH2:22]4)[N:20]=3)=[CH:11][N:10]=2)=[CH:5][CH:4]=1.[N:51]1[CH:56]=[CH:55][CH:54]=[C:53]([CH2:57][N:58]2[CH2:63][CH2:62][NH:61][CH2:60][CH2:59]2)[CH:52]=1>>[CH3:48][O:47][C:44]1[CH:45]=[CH:46][C:41]([CH2:40][N:8]([CH2:7][C:6]2[CH:49]=[CH:50][C:3]([O:2][CH3:1])=[CH:4][CH:5]=2)[C:9]2[N:10]=[CH:11][C:12]([C:15]3[C:16]4[CH2:29][CH2:28][N:27]([C:30]5[CH:38]=[CH:37][C:33]([C:34]([N:61]6[CH2:62][CH2:63][N:58]([CH2:57][C:53]7[CH:52]=[N:51][CH:56]=[CH:55][CH:54]=7)[CH2:59][CH2:60]6)=[O:36])=[CH:32][C:31]=5[F:39])[C:17]=4[N:18]=[C:19]([N:21]4[CH2:26][CH2:25][O:24][CH2:23][CH2:22]4)[N:20]=3)=[CH:13][N:14]=2)=[CH:42][CH:43]=1

Komponenten

3

Edukt 2

HCID 1569751-[(Pyridin-3-yl)methyl]piperazineHCID 592443954-(4-{2-[Bis-(4-methoxy-benzyl)-amino]-pyrimidin-5-yl}-2-morpholin-4-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-7-yl)-3-fluoro-benzoic acid

Produkt 1

HCID 67386155[4-(4-{2-[Bis-(4-methoxy-benzyl)-amino]-pyrimidin-5-yl}-2-morpholin-4-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-7-yl)-3-fluoro-phenyl]-(4-pyridin-3-ylmethyl-piperazin-1-yl)-methanone

Versuchsvorschrift

Using 4-(4-{2-[bis-(4-methoxy-benzyl)-amino]-pyrimidin-5-yl}-2-morpholin-4-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-7-yl)-3-fluoro-benzoic acid (54 mg) and 1-pyridin-3-ylmethyl-piperazine (22 mg) obtained in Step A in Example 1-D-315 instead of 3-(aminomethyl)pyridine used in Step B in Example 1-D-19, treatment was carried out in the same manner as Step B in Example 1-D-19, to obtain a crude product of [4-(4-{2-[bis-(4-methoxy-benzyl)-amino]-pyrimidin-5-yl}-2-morpholin-4-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-7-yl)-3-fluoro-phenyl]-(4-pyridin-3-ylmethyl-piperazin-1-yl)-methanone, and then the PMB groups were removed according to the above Deprotection method 3, to obtain the desired compound (D-315) as a yellow powder (32.0 mg, 83%).

Quellen und Nachweise

ORD-Eintrag
ord-4ccc423b8f8247398f71ec71badb7435
Quelldatensatz
uspto-grants-2011_09
Patentnummer
US08022205B2

Verknüpfte Notizen

Wird geladen…